Regeneron’s POTS antibody curbs heart rate spikes, teeing up Phase 3 trial
A single dose of Regeneron Pharmaceuticals’ investigational monoclonal antibody reduced orthostatic heart rate at eight days for patients with a…
A single dose of Regeneron Pharmaceuticals’ investigational monoclonal antibody reduced orthostatic heart rate at eight days for patients with a…